Novel non-nucleoside human cytomegalovirus inhibitors based upon TSAO nucleoside derivatives: Structure-activity relationships

Nucleosides, Nucleotides and Nucleic Acids

Volumn 26, Issue 6-7, 2007, Pages 625-628

  De Castro, Sonia ^a   Andrei, Graziela ^b   Snoeck, Robert ^b   Balzarini, Jan ^b   Camarasa, María José ^a   Velázquez, Sonsoles ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Cytomegalovirus; HCMV inhibitors; TSAO nucleosides; Ureidonucleosides

Indexed keywords

ANTIVIRUS AGENT; DNA POLYMERASE; NUCLEOSIDE DERIVATIVE;

AMINO ACID SYNTHESIS; ANTIVIRAL ACTIVITY; BIOLOGICAL ACTIVITY; CONFERENCE PAPER; HUMAN; HUMAN CYTOMEGALOVIRUS; STRUCTURE ACTIVITY RELATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; HUMANS; NUCLEOSIDES; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 36949009853     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770701490431     Document Type: Conference Paper

References (8)

1. Pass, R.F. Cytomegalovirus. In Fields Virology. Lippincott, Williams & Wilkins, Philadelphia, 2001, Vol 2 . 4th ed., pp. 2675-2705.
2. Trincado, D.E.; Scott, G.M.; White, P.A.; Hunt, C.; Rasmussen, L.; Rawlinson, W.D. Human cytomegalovirus strains associated with congenital and perinatal infections. J. Medical Virology 2000, 61, 481-487.
3. Yeh, R. and Cohen, D.M. Pharmacology of viral replication. In Principles of Pharmacology: The Patophysiologic Basis Of Drug Therapy. Lippincott, Williams & Wilkins, Baltimore, 2004, pp. 545-564.
4. Villareal, E.C. Current and potential therapies for the treatment of herpes-virus infections. Progress in Drug Research 2003, 60, 263-307.
5. De Castro, S.; Lobatón, E.; Pérez-Pérez, M.J.; San-Félix, A.; Cordeiro, A.; Andrei, G.; Snoeck, R.; De Clercq, E.; Balzarini, J.; Camarasa, M.J.; Velázquez. S. Novel [2′,5′- Bis-O-(tert-butyldimethylsilyl)-β-D-ribofuronosyl] -3″-spiro-5″-(4″-amino-1″,2″-oxathiole-2″, 2″-dioxide) derivatives with anti-HIV-1 and anti human cytomegalovirus activity. J. Medicinal Chemistry 2005, 48, 1158-1168.
6. Camarasa, M.J.; San-Félix, A.; Velázquez, A.; Pérez-Pérez, M.J.; Gago, F.; Balzarini, J. TSAO compounds: The comprehensive store of a unique family of HIV-1 specific inhibitors of reverse transcriptase. Current Topics Medicinal Chem. 2004, 4, 945-963.
7. Ingate, S.; Pérez-Pérez, M.J.; De Clercq, E.; Balzarni, J.; Camarasa, M.J. Synthesis and anti-HIV-1 activity of novel TSAO-T derivatives modified at the 2′- and 5′-position of the sugar moiety. Antiviral Research 1995, 27, 281-299.
8. Pérez-Pérez, M.J.; San-Félix, A.; Balzarini, J.; De Clercq, E.; Camarasa, M.J. TSAO analogues. Stereospecific and anti-HIV-1 activity of 1-[2′,5′-Bis-O-(tert-butyldimethylsilyl)-β- D-ribofuranoxyl]-3-spiro-5″-(4″-amino-1″,2″-oxathiole- 2″,2″-dioxide) pyrimidine and pyrimidine-modified nucleosides. J. Medicinal Chem. 1992, 35, 2988-2995.